Blockade of the inflammatory cytokine tumor necrosis factor (TNF) in depressed patients with increased inflammation has been associated with decreased depressive symptoms. Nevertheless, the impact of TNF blockade on sleep in depressed patients has not been examined. Accordingly, sleep parameters were measured using polysomnography in 36 patients with treatment resistant major depression at baseline and 2 weeks after 3 infusions (week 8) of either the TNF antagonist infliximab (n = 19) or placebo (n = 17). Markers of inflammation including c-reactive protein (CRP) and TNF and its soluble receptors were also assessed along with depression measured by the 17-item Hamilton Depression Rating Scale. No differences in sleep parameters were found as a function of infliximab treatment over time. Nevertheless, wake after sleep onset (WASO), the spontaneous arousal index and sleep period time significantly decreased, and sleep efficiency significantly increased, from baseline to week 8 in infliximab-treated patients with high (CRP > 5 mg/L) (n = 9) versus low inflammation (CRP 6 5 mg/L) (n = 10), controlling for changes in scores of depression. Stage 2 sleep also significantly decreased in infliximab-treated patients with high versus low inflammation. Decreases in soluble TNF receptor 1 (sTNFR1) significantly correlated with decreases in WASO and increases in sleep efficiency in infliximab-treated subjects with high inflammation. Placebo-treated subjects exhibited no sleep changes as a function of inflammation, and no correlations between inflammatory markers and sleep parameters in placebo-treated patients were found. These data suggest that inhibition of inflammation may be a viable strategy to improve sleep alterations in patients with depression and other disorders associated with increased inflammation.
Introduction
Alterations in sleep are among the most common symptoms of major depression, with greater than 75 percent of depressed patients reporting significant sleep disruption (Lam, 2006; Nutt et al., 2008; Tsuno et al., 2005) . Sleep disturbances in depression are associated with decreased quality of life, increased risk for suicide, and an impaired response to conventional antidepressant therapy, which occurs in up to 30% of depressed patients (Nutt et al., 2008; Rush et al., 2006) . Compared to healthy controls, patients with major depression have consistently demonstrated changes in sleep architecture as measured by polysomnography including decreases in sleep efficiency, slow wave sleep, Stage 2 sleep and the latency to rapid eye movement (REM) sleep as well as increases in REM density (Thase, 2006, Benca and Peterson, 2008) (Arfken et al., 2014) .
One pathophysiologic mechanism that may be involved in some of the sleep changes found in depression is inflammation (Benedict et al., 2009; Imeri and Opp, 2009; Irwin et al., 2008; Krueger, 2008; Krueger et al., 2001; Motivala et al., 2005; Opp, 2005) . Markers of inflammation, including inflammatory cytokines and their receptors, acute phase proteins such as c-reactive protein (CRP), chemokines, and adhesion molecules have been found to be elevated in a significant proportion of depressed patients in multiple studies (Dowlati et al., 2010; Miller et al., 2009 ). Moreover, a rich literature in laboratory animals and humans has shown that inflammatory cytokines such as tumor necrosis factor (TNF), interleukin (IL)-6, and IL-1 induce marked alterations in sleep architecture (Imeri and Opp, 2009; Krueger, 2008; Opp, 2005) . 
